Sartorius Stedim Biotech and RAUMEDIC Sign Partnership Agreement
News May 20, 2011
Sartorius Stedim Biotech (SSB), has announced the signing of a global partnership agreement. This covers arrangements concerning the mutual development of innovative fluid systems and marketing of single-use tubing, which RAUMEDIC produces for and will supply to Sartorius Stedim Biotech on a long-term basis.
Sartorius Stedim Biotech will be combining its designing, manufacturing and validation expertise in single-use systems for biopharmaceutical applications with RAUMEDIC proficiency in the development and manufacture of tubing for medical and biopharmaceutical use.
The alliance will provide innovative, high-quality and reliable fluid handling systems to biopharmaceutical manufacturers. Through this strategic partnership with RAUMEDIC, Sartorius Stedim Biotech will substantially expand its product and service portfolio in the area of liquid transfer technologies.
The companies will strengthen and develop their existing long-term collaboration and merge their expertise for generating new tubing technologies and validation standards.
With a new product line, TuFlux, which will soon be launched, Sartorius Stedim Biotech will supply its customers with highly validated polymer and silicone tubing on single-use assemblies as well as stand-alone tubing coils, along with comprehensive validation packages.
According to the agreement, Sartorius Stedim Biotech will offer its products backed by RAUMEDIC’s support and assistance in order to develop customized solutions and to provide stronger validation and technical support as well as process improvements.
Jean-Marc Cappia, Vice President of Fluid Management Technologies of Sartorius Stedim Biotech, acknowledges the agreement as an important milestone in expanding SSB’s product portfolio. “More than ever, we offer the full capabilities of single-use technologies. For our customers of the biopharmaceutical industry, this partnership will yield a powerful combination of single-use bags, filters, connectors, sensors and tubing systems and services. Our long-term expertise in characterizing extractables in filters and bags will benefit our tubing technology and hence we will be offering more comprehensive validation packages for our single-use solutions,” he explained.
RAUMEDIC is bringing to Sartorius Stedim Biotech more than 60 years of technical expertise and manufacturing excellence in the area of polymer-based systems and components for medical and pharmaceutical applications. The company is renown in material development, compounding of raw materials, and extrusion technologies of all kinds for polymer and elastomer tubing.
Martin Bayer, CEO of RAUMEDIC, explained the benefits for the biopharmaceutical customers. “This alliance will provide integrated, single-use systems to the global biopharmaceutical industry, which have been developed and harmonized by two strong partners in this area,” he said.
Mycophenolic acid (MPA), discovered in 1893, was the first natural antibiotic to be isolated and crystallized in human history, however, the biogenesis of such an old and important molecule was an unsolved mystery for more than a century. Scientists have now cracked this intriguing black box by fully elucidating the biosynthetic pathway of MPA.READ MORE
Synthetic biologists look to re-engineer cells to make complex molecules for specific needs, including pharmaceuticals. But the trial-and-error process is difficult and time-consuming. Now, by combining two state-of-the-art research approaches, researchers have created a fast, efficient way to engineer and analyze metabolic pathways.READ MORE